Blinatumomab + Chemotherapy for Leukemia

"In addition to Norton Children's Hospital in Louisville, Kentucky, Morristown Medical Center in Morristown, New jersey, and Santa Barbara Cottage Hospital in Santa Barbara, California, this study is also being conducted at 100 other medical facilities."

"This trial's primary goal is to compare Disease free survival (DFS) rates in patients with higher risk features (SR-High) or standard risk average (SR-Avg) B-ALL, with the addition of blinatumomab. The trial will run for 5.1 years and secondary outcomes include DFS for patients with standard-risk favorable (SR-Fav) B-ALL when treated with a standard chemotherapy regimen, as well as DFS of DS-High B-ALL patients when intensive elements of chemotherapy are replaced with 3 cycles of blinatumomab. Additionally, the study aims to compare"

"Indeed, clinicaltrials.gov reflects that this clinical trial is still looking for participants. This research was originally posted on 6/28/2019 and has been updated as recently as 11/4/2022."

"Enrollment for this clinical trial is only possible for those between 1 and 31 years old."

"That is correct. The clinical trial was posted on 6/28/2019 and was most recently updated on 11/4/2022. The study is admitting 6720 participants across 100 locations."

"Arm B (SR-Avg experimental) of this Phase 3 clinical trial has received a score of 3 for safety by our analysts at Power. This is due to the presence of some efficacy data as well as multiple rounds of safety data."

"Arm B (SR-Avg experimental) is the most common intervention for ulcerative colitis. It is also taken to treat other conditions including multiple myeloma, eye, and subarachnoid block."

"There are a total of 2344 clinical trials ongoing for Arm B (SR-Avg experimental). 541 of these are in Phase 3. The epicentre for these trials is Changsha, Hunan, but there are 78256 total locations running these trials."

"This clinical trial is recruiting 6720 patients, between the ages of 1 and 31, who have down syndrome. In order to participate, patients must meet the following criteria: Patients must be between 1 and 31 years of age (B-ALL patients with DS)., Patients must be between 1 and 31 years of age (B-LLy patients with or without DS)., B-ALL patients without DS must have an initial white blood cell count < 50,000/uL (performed within 7 days prior to enrollment)., B-ALL patients with DS are eligible regardless of the presenting white blood cell count (WBC"